OncoCyte Corporation (OCX) DCF Valuation

OncoCyte Corporation (OCX) DCF Valuation
  • ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
  • ✓ Design Profissional: Modelos Confiáveis ​​E Padrão Da Indústria
  • ✓ Pré-Construídos Para Uso Rápido E Eficiente
  • ✓ Não É Necessária Experiência; Fácil De Seguir

OncoCyte Corporation (OCX) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Enhance your investment choices with the OncoCyte Corporation (OCX) DCF Calculator! Utilize real OncoCyte financial data, adjust growth predictions and expenses, and instantly observe how these modifications affect the intrinsic value of OncoCyte Corporation (OCX).


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue .0 1.2 7.7 1.0 1.5 1.8 2.1 2.4 2.8 3.3
Revenue Growth, % 0 0 535.44 -87.6 56.89 17.32 17.32 17.32 17.32 17.32
EBITDA -21.9 -30.5 -48.5 -13.3 -23.1 -1.1 -1.2 -1.5 -1.7 -2.0
EBITDA, % 100 -2511.51 -627.11 -1389.87 -1538.46 -60 -60 -60 -60 -60
Depreciation .3 .4 4.2 5.2 1.7 1.4 1.6 1.9 2.2 2.6
Depreciation, % 100 32.4 54.42 544.89 111.78 77.36 77.36 77.36 77.36 77.36
EBIT -22.2 -30.9 -52.7 -18.5 -24.8 -1.1 -1.2 -1.5 -1.7 -2.0
EBIT, % 100 -2543.91 -681.53 -1934.76 -1650.23 -60 -60 -60 -60 -60
Total Cash 22.5 7.8 36.5 20.4 9.4 1.8 2.1 2.4 2.8 3.3
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .0 .2 1.4 2.0 .5
Account Receivables, % 100 16.69 18.6 210.02 32.2
Inventories .0 .0 .3 2.1 .0 .7 .8 1.0 1.2 1.4
Inventories, % 100 0 3.93 221.4 0 40.79 40.79 40.79 40.79 40.79
Accounts Payable .5 .4 1.8 1.3 1.0 1.1 1.3 1.6 1.8 2.2
Accounts Payable, % 100 35.53 23.42 130.79 63.41 64.47 64.47 64.47 64.47 64.47
Capital Expenditure -.9 -1.2 -2.2 -4.3 -.3 -.9 -1.0 -1.2 -1.4 -1.7
Capital Expenditure, % 100 -100.9 -29.08 -453.03 -18.7 -49.56 -49.56 -49.56 -49.56 -49.56
Tax Rate, % -11.77 -11.77 -11.77 -11.77 -11.77 -11.77 -11.77 -11.77 -11.77 -11.77
EBITAT -22.1 -29.7 -46.0 -73.1 -27.7 -1.0 -1.2 -1.4 -1.7 -1.9
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -22.2 -30.8 -44.2 -75.2 -23.0 -1.5 -.7 -.8 -1.0 -1.2
WACC, % 8.46 8.44 8.38 8.47 8.47 8.44 8.44 8.44 8.44 8.44
PV UFCF
SUM PV UFCF -4.2
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) -1
Terminal Value -18
Present Terminal Value -12
Enterprise Value -16
Net Debt -7
Equity Value -10
Diluted Shares Outstanding, MM 8
Equity Value Per Share -1.28

What You Will Get

  • Comprehensive OCX Financials: Access to historical and projected data for precise valuation.
  • Customizable Inputs: Adjust WACC, tax rates, revenue growth, and capital expenditures as needed.
  • Dynamic Calculations: Intrinsic value and NPV are computed in real-time.
  • Scenario Analysis: Explore various scenarios to assess OncoCyte’s future performance.
  • User-Friendly Design: Designed for professionals while remaining approachable for newcomers.

Key Features

  • Real-Life OCX Data: Pre-filled with OncoCyte Corporation’s historical financials and future projections.
  • Fully Customizable Inputs: Modify revenue growth, profit margins, WACC, tax rates, and capital expenditures.
  • Dynamic Valuation Model: Automatic updates to Net Present Value (NPV) and intrinsic value based on your adjustments.
  • Scenario Testing: Develop multiple forecasting scenarios to evaluate different valuation results.
  • User-Friendly Design: Intuitive, organized, and tailored for both professionals and novices.

How It Works

  • 1. Access the Template: Download and open the Excel file containing OncoCyte Corporation’s (OCX) preloaded data.
  • 2. Modify Assumptions: Adjust key inputs such as growth rates, WACC, and capital expenditures.
  • 3. Analyze Results Immediately: The DCF model automatically calculates intrinsic value and NPV.
  • 4. Explore Scenarios: Evaluate various forecasts to assess different valuation possibilities.
  • 5. Present with Assurance: Share professional valuation insights to back your decision-making process.

Why Choose This Calculator for OncoCyte Corporation (OCX)?

  • Accuracy: Utilizes real OncoCyte financial data for precise calculations.
  • Flexibility: Allows users to easily test and adjust inputs as needed.
  • Time-Saving: Avoid the complexities of creating a DCF model from the ground up.
  • Professional-Grade: Crafted with the expertise and standards expected by CFOs.
  • User-Friendly: Intuitive design makes it accessible for users with varying levels of financial expertise.

Who Should Use This Product?

  • Individual Investors: Make informed decisions about buying or selling OncoCyte Corporation (OCX) stock.
  • Financial Analysts: Streamline valuation processes with ready-to-use financial models for OncoCyte Corporation (OCX).
  • Consultants: Deliver professional valuation insights on OncoCyte Corporation (OCX) to clients quickly and accurately.
  • Business Owners: Understand how biotech companies like OncoCyte Corporation (OCX) are valued to guide your own strategy.
  • Finance Students: Learn valuation techniques using real-world data and scenarios related to OncoCyte Corporation (OCX).

What the Template Contains

  • Pre-Filled Data: Includes OncoCyte Corporation’s historical financials and projections.
  • Discounted Cash Flow Model: Editable DCF valuation model with automated calculations.
  • Weighted Average Cost of Capital (WACC): A dedicated sheet for calculating WACC based on user-defined inputs.
  • Key Financial Ratios: Assess OncoCyte Corporation’s profitability, efficiency, and leverage.
  • Customizable Inputs: Easily modify revenue growth, margins, and tax rates.
  • Clear Dashboard: Visual representations and tables summarizing essential valuation outcomes.

No products were found matching.